Shandong Weigao Medical Polymer Debt/Equity Ratio 2012-2024 | SHWGF

Shandong Weigao Medical Polymer debt/equity ratio from 2012 to 2024. Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.

Shandong Weigao Medical Polymer Debt/Equity Ratio 2012-2024 | SHWGF

Shandong Weigao Medical Polymer debt/equity ratio from 2012 to 2024. Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$205.7B
Stryker (SYK)$140B
Boston Scientific (BSX)$123.1B
Medtronic (MDT)$115.5B
EssilorLuxottica (ESLOY)$107.3B
Lonza Group Ag (LZAGY)$45.5B
Haleon (HLN)$44B
GE HealthCare Technologies (GEHC)$39.7B
ResMed (RMD)$35.9B
Terumo (TRUMY)$28.3B
Koninklijke Philips (PHG)$24.9B
Zimmer Biomet Holdings (ZBH)$21.4B
Baxter (BAX)$18.3B
Insulet (PODD)$16.5B
Smith & Nephew SNATS (SNN)$11B
Bio-Rad Laboratories (BIO)$10.3B
BellRing Brands (BRBR)$8.6B
Demant (WILYY)$8.4B
Lantheus Holdings (LNTH)$7.5B
ICU Medical (ICUI)$4.2B
TG Therapeutics (TGTX)$4.2B
Prestige Consumer Healthcare (PBH)$3.7B
Haemonetics (HAE)$3.7B
Envista Holdings (NVST)$3.6B
Perrigo (PRGO)$3.6B
Neogen (NEOG)$3.1B
GN Store Nord (GNNDY)$3B
QuidelOrtho (QDEL)$2.6B
Agios Pharmaceuticals (AGIO)$2.6B
Green Thumb Industries (GTBIF)$2.2B